▲ +27.39% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Unity Biotechnology in the last 3 months. The average price target is $6.00, with a high forecast of $12.00 and a low forecast of $4.00. The average price target represents a 27.39% upside from the last price of $4.71.
The current consensus among 6 contributing investment analysts is to hold stock in Unity Biotechnology. This Hold consensus rating has held steady for over two years.
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.